Market Signal Briefing

Combined Company Expected to Retain Sphere3D's Name and US Listing (NASDAQ: ANY)

Toronto, Ontario and Stamford, Connecticut--(Newsfile Corp. - March 5, 2026) - Cathedra Bitcoin Inc. (TSXV: CBIT) (OTCQB: CBTTF) ("Cathedra"), a company that builds, develops and operates power infrastructure facilities for use in high density computing, and Sphere 3D Corp. (NASDAQ: ANY) ("Sphere" and together with Cathedra, the "Parties"), a bitcoin mining company, are pleased to announce that they have entered into a definitive agreement to combine in an all-stock transaction, which is expected to create a next-generation high density computing power infrastructure company focused on high-performance compute, digital assets, energy optimization, and development of power and infrastructure. The combined company (the "Combined Company") will bring together Sphere's established capital markets access including its Nasdaq listing, strong balance sheet, liquidity, and efficient fleet of miners with Cathedra's robust energy portfolio, proven infrastructure development expertise, bitcoin mining operations, energy-first site selection strategy, and disciplined capital allocation. The strategic combination is expected to enable near-term vertical integration, positioning the Combined Company to accelerate scalable, high-efficiency deployment across North America by leveraging a focus on low-cost power, operational efficiency, and long-term shareholder value creation. Under the terms of the definitive arrangement agreement, entered into on March 5, 2026 (the "Agreement"), Sphere has agreed to acquire all of the issued and outstanding shares of Cathedra (the "Transaction"), subject to customary closing conditions, including regulatory, court, and shareholder approvals, such that upon consummation of the Transaction, Cathedra will be a wholly-owned subsidiary of Sphere.

Upon completion of the Transaction, Cathedra security holders will receive common shares of Sphere (the "Sphere Common Shares") and/or securities exercisable or convertible into Sphere Common Shares totaling approximately 49% of all of the issued and outstanding share capital of Sphere immediately following closing on a partially diluted basis. The Combined Company is expected to retain Sphere's name and listing on NASDAQ under the symbol "ANY".

"We are thrilled to unite Cathedra with Sphere in this transformative transaction," remarked Joel Block, CEO of Cathedra and expected CEO of the Combined Company. "The Sphere team has navigated a challenging period in bitcoin mining with exceptional discipline, emerging with a strong balance sheet and a highly efficient fleet of mining machines. By combining our existing data center portfolio, development capabilities, and operational expertise with Sphere's established public market access and asset base, I believe we are creating a vertically integrated powerhouse. When I joined Cathedra, our priorities were clear: reduce debt, build more data facilities, and improve access to the public markets. This business combination addresses these objectives and allows management to focus on building a category defining company in this new space of high-density computing infrastructure in the United States. We expect that this business combination will deliver immediate scale, enhance operational efficiency, improve profitability, while accelerating our growth strategy. With an ambitious and now significantly accelerated roadmap, we plan to rapidly expand power capacity, execute disciplined development across diversified, low-cost energy sites, optimize operations, and pursue high performance computing opportunities alongside bitcoin mining. With greater scale, liquidity, and vertical integration, we believe we will be positioned to capture significant upside in the evolving digital infrastructure landscape."

"This Transaction represents an important milestone for Sphere," said Kurt Kalbfleisch, Chief Executive Officer of Sphere. "Combining our platform and strong balance sheet with Cathedra's energy assets and disciplined, energy-first operating model, we can create a uniquely powerful, vertically integrated platform. On completion of the Transaction, we expect to be exceptionally well-positioned to scale, drive operational efficiencies, seize high performance compute opportunities, and deliver compelling long-term value."

Expected Strategic Benefits:

Improved scale and expanded US operating footprint: The Combined Company expects to initially own and operate a portfolio of 53 megawatts ("MW") of power capacity across five data centers in Iowa, Kentucky, and Tennessee.

Platform Expansion into High-Performance Compute: With growing demand for compute-intensive workloads, the Combined Company intends to evaluate selective expansion into adjacent high-performance compute and AI infrastructure opportunities, leveraging existing power relationships and site capabilities with the goal of maximizing the value of its electrons. This expanded operating scale expects to improve profitability, spreading fixed overhead costs over a larger revenue and asset base.

Diversified revenue streams across proprietary mining and hosting services: The integration of Sphere's mining machine fleet with Cathedra's data center operations would diversify the Combined Company's revenue streams across proprietary mining and hosting services, offering exposure to high-upside, volatile mining economics with expected downside protection via fixed-margin hosting contracts with third parties.

Strong growth prospects through scalable development model and access to capital: With Cathedra's low-cost development model and infrastructure-first approach, coupled with Sphere's capital markets expertise and access to liquidity, the Combined Company expects to capitalize on a robust pipeline of over 100 MW of potential expansion opportunities to further expand its portfolio of infrastructure assets. In the past six months, Cathedra's new leadership team has successfully increased its power capacity by 50% online and developed a robust pipeline.

Experienced leadership team with strategic vision: Cathedra CEO Joel Block will assume the role of CEO of the Combined Company and join the board of directors. Joel brings extensive experience in both private and public capital markets and operating in the data center and bitcoin mining arena. Sphere CEO and CFO Kurt Kalbfleisch will resign as CEO and remain in his current role as CFO and join the board of directors of the Combined Company, contributing over two decades of executive leadership experience at multiple NASDAQ-listed companies. Other key members from Sphere and Cathedra are expected to remain in key roles as the Combined Company looks to execute on a robust growth and development plan.

Upon completion of the Transaction, the Combined Company's bitcoin mining operations and balance sheet are expected to include:

Managed power capacity of 53 MW at five data centers across three U.S. states, including data centers owned by the Combined Company and those leased from and/or operated by third parties; and

1.2 EH/s of installed proprietary mining hash rate across data centers owned by the Combined Company and third-party hosting providers.

Board and Management

Upon closing of the Transaction and subject to applicable approvals, the Combined Company's board of directors and management team is expected to consist of the following individuals:

Board of DirectorsManagement TeamTim Hanley, ChairMarcus Dent Kurt KalbfleischNicholas GatesJoel BlockJoel Block, Chief Executive OfficerKurt Kalbfleisch, Chief Financial OfficerTiah Reppas, Chief Accounting OfficerThe Combined Company will be led by a seasoned management team and supported by a strong board of directors with deep expertise in bitcoin mining, digital infrastructure, energy optimization, and capital markets. Joel Block, the current CEO of Cathedra, brings more than 20 years of executive experience in operations, sales, capital markets, and finance. Kurt Kalbfleisch, the current CEO and CFO of Sphere, has guided the company through industry volatility since 2014, first as CFO and then as CEO. The board will feature experienced independent directors: Tim Hanley, a Sphere director and veteran business executive with deep accounting expertise; Marcus Dent, a current Cathedra director and thought leader in the bitcoin industry, and Nicholas Gates, Managing Director at Priority Power Management, an Arlington, Texas-based leader in energy management, procurement, and infrastructure development. Together, Mr. Dent, Mr. Hanley, and Mr. Gates will serve as independent directors, focused on robust governance, diverse strategic perspectives, and focused execution.

Additional Transaction Details

Pursuant to the terms of the Agreement, Cathedra will amalgamate with S3D Acquisition Corp., a wholly owned subsidiary of Sphere formed to complete the Transaction. Holders of Cathedra subordinate voting shares ("Cathedra SV Shares") will receive 0.123014 of a Sphere Common Share for each Cathedra SV Share held and holders of Cathedra multiple voting shares ("Cathedra MV Shares") will receive 12.3014 Sphere Common Shares for each Cathedra MV Share held, which provide economically equivalent consideration for both classes of shares. Cathedra's outstanding warrants, stock options and certain restricted share units will be exchanged for corresponding Sphere securities in accordance with the applicable exchange ratio. The remaining restricted share units will fully vest immediately prior to closing, and the holders thereof will receive Sphere Common Shares in accordance with the applicable exchange ratio. In addition, certain key Cathedra shareholders will be subject to a 7% post-closing ownership cap, with any consideration that would otherwise exceed such cap to be received in a new series of Sphere non-voting preferred shares having equivalent economic value.

The Transaction will be completed by way of a court-approved plan of arrangement under the Business Corporations Act (British Columbia) and will require the following approvals: (i) the approval of the British Columbia Supreme Court (the "Court"), (ii) the approval by 66⅔% of the votes cast by holders of Cathedra SV Shares and Cathedra MV Shares, voting as a single class, at a meeting of Cathedra's securityholders (the "Cathedra Meeting"), (iii) the approval by 66⅔% of the votes cast by holders of Cathedra SV Shares, Cathedra MV Shares, Cathedra warrants, Cathedra stock options and Cathedra restricted share units, voting as a single class, at the Meeting, and (iv) the approval of a simple majority of the votes cast by Sphere shareholders at a meeting of Sphere shareholders (the "Sphere Meeting", and together with the Cathedra Meeting, the "Meetings").

An information circular or proxy statement (each, a "Disclosure Document") detailing the terms and conditions of the Transaction will be mailed to the Cathedra shareholders and Sphere shareholders, respectively, in connection with their respective Meetings. All shareholders are urged to read the applicable Disclosure Document once available, as it will contain important additional information concerning the Transaction.

The Agreement includes standard deal protection provisions, including non-solicitation, right-to-match, and fiduciary out provisions, as well as certain representations, covenants and conditions that are customary for a transaction of this nature, along with a reciprocal termination fee payable in certain circumstances. The completion of the Transaction remains subject to customary conditions, including receipt of all necessary Court, shareholder and regulatory approvals.

None of the securities to be issued pursuant to the Transaction have been or will be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and securities issued in the Transaction are anticipated to be issued in reliance on the exemption from the registration requirements of the U.S. Securities Act provided by Section 3(a)(10) thereof and will be issued pursuant to similar exemptions from applicable state securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

Board Recommendations & Voting Support

Each of the board of directors of Cathedra and Sphere have unanimously approved the Transaction and each board of directors recommends that its respective shareholders vote in favor of the Transaction at the applicable Meeting.

Directors and officers of Cathedra beneficially owning an aggregate number of Cathedra SV Shares and Cathedra MV Shares which represent approximately 70% of the currently outstanding Cathedra SV Shares and Cathedra MV Shares combined (on a fully converted basis) have entered into customary support agreements with Sphere to vote their shares in favor of the Transaction at the Cathedra Meeting. Directors and officers of Sphere holding an aggregate number of Sphere Common Shares which represent approximately 3% of the currently outstanding Sphere Common Shares have entered into customary support agreements with Cathedra to vote their shares in favor of the Transaction at the Sphere Meeting.

Stock Exchange Listing and SEDAR+

If the Transaction is completed, the Cathedra SV Shares will be delisted from the TSXV and the OTCQB and the Sphere Shares are expected to continue trading on NASDAQ under the ticker "ANY". A copy of the Agreement will be available through Cathedra's and Sphere's filings with the applicable securities regulatory authorities on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov, respectively.

Advisors and Counsel

Dumoulin Black LLP is acting as Canadian legal counsel to Cathedra and Greenberg Traurig, LLP is acting as U.S. legal counsel to Cathedra. Evans & Evans, Inc. was the fairness opinion provider to Cathedra on this transaction.

Second Gate Advisory LLC is acting as strategic advisor to Sphere, Meretsky Law Firm is acting as Canadian legal counsel to Sphere and Pryor Cashman LLP is acting as U.S. legal counsel to Sphere. Rosenblatt Securities was the fairness opinion provider to Sphere 3D on this transaction.

Amendment to Employment Agreement

In connection with the Transaction, Cathedra and Joel Block have mutually agreed to amend Mr. Block's employment agreement to restructure his existing transaction bonus. The amended bonus of US$1.6 million will be subject to the achievement of certain performance milestones of the Combined Company designed to promote the long-term success of the Combined Company and align management incentives with shareholder value creation.

About Cathedra Bitcoin Inc.

Cathedra Bitcoin Inc. develops and operates digital infrastructure assets across North America. Cathedra hosts bitcoin mining clients across its portfolio of four data centers (45 megawatts total) in Tennessee and Kentucky. Cathedra also operates a fleet of proprietary bitcoin mining machines at its own and third-party data centers, producing approximately 400 PH/s of hash rate. Cathedra is headquartered in Vancouver and its shares trade on the TSX Venture Exchange under the symbol CBIT and in the OTC market under the symbol CBTTF. For more information about Cathedra, visit cathedra.com.

About Sphere 3D Corp.

Sphere 3D Corp. (NASDAQ: ANY) is a Bitcoin miner, growing its digital asset mining operation through the capital-efficient procurement of next-generation mining equipment and partnering with data center operators. Sphere 3D is dedicated to increasing shareholder value. For more information about Sphere 3D, please visit Sphere3D.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements Disclaimer

This news release contains certain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities laws that are based on expectations, estimates and projections as at the date of this news release. The forward-looking statements are intended to be subject to the safe harbor provided by Section 27A of the U.S. Securities Act, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. The information in this release about future plans and objectives of Cathedra and Sphere, are forward-looking information. Other forward-looking information includes, but is not limited to, information concerning: the intentions and future actions of senior management, the intentions, plans and future actions of the Cathedra and Sphere, as well as their ability to successfully mine digital currency; the timing and anticipated completion of the Transaction, and court and shareholder approvals for same; Cathedra's and Sphere's expectation to hold shareholder meetings to approve various items related to the Transaction; revenue and capacity projections of the Combined Company; the expected composition of the board of directors and management of the Combined Company; timing of regulatory approvals for the Transaction; the expected benefits from the Transaction; the combination of Cathedra's business and Sphere's business; the impact that the Transaction is expected to have on the business operations of the Combined Company including without limitation, the expected growth and capabilities of the Combined Company; the expected improved profitability and increased liquidity of the Combined Company, the expectation of synergies and efficiencies among the Combined Company, the construction and operation of expanded blockchain infrastructure as currently planned, the creation of long-term value for the shareholders of the Combined Company, the potential to accelerate growth; planned growth, vertical integration and expansion into high-performance compute and AI infrastructure; projected reductions in power costs; the anticipated assets, operations and balance sheet of the combined company following closing; expected operational, cost and procurement synergies; the delisting of Cathedra shares and continued NASDAQ listing of Sphere shares; the preparation, filing and mailing of disclosure documents in connection with the Transaction; and the regulatory environment of cryptocurrency in applicable jurisdictions. Any statements that involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "targets", "estimates", "believes", "contemplates", "predicts", "potential", "continue" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "should", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information.

This forward-looking information is based on reasonable assumptions and estimates of management of the parties at the time it was made, including, without limitation, assumptions that the parties will be able to obtain the requisite regulatory, court, shareholder and third party approvals and satisfy the other conditions to the consummation of the Transaction on the proposed schedule and terms and conditions set out in the Agreement; that the Agreement will not be terminated prior to the closing the Transaction; that the Transaction will be completed in accordance with the terms and conditions of the Agreement and within the timeframe expected; that no material adverse changes will occur in the businesses, operations or financial condition of either party prior to closing; that no unanticipated events will occur that will delay or prevent the completion of the Transaction; the ability of the Combined Company to successfully integrate the businesses and realize anticipated synergies, cost savings and operational efficiencies; the accuracy of projected power costs, energy availability and hosting arrangements; the continued availability of low-cost and reliable power; the performance and deployment of mining equipment and infrastructure; the availability of growth capital on acceptable terms; the ability to execute expansion plans on schedule and within budget; market conditions for bitcoin mining and high-performance computing infrastructure; the price of bitcoin and other digital assets; network difficulty and hash rate conditions; regulatory and tax stability in applicable jurisdictions; general economic, financial and capital markets conditions; and that the parties will have access to the financial and other resources required to carry out their business plans as currently anticipated. The parties have also assumed that no significant events occur outside of their normal courses of business.

Additionally, these forward-looking statements may be affected by risks and uncertainties in the business of Cathedra and Sphere and general market conditions. Investors are cautioned that forward-looking statements are not based on historical facts but instead reflect Cathedra and Sphere's respective management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Cathedra and Sphere believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed thereon, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Combined Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking statements are the following: the ability to consummate the Transaction; the ability to obtain requisite regulatory, court, shareholder and third party approvals, the satisfaction of other conditions to the consummation of the Transaction on the proposed schedule, or at all and on the terms and conditions set out in the Agreement; the potential impact of the announcement or consummation of the Transaction on relationships, including with regulatory bodies, employees, customers and competitors; the anticipated timing of mailing Disclosure Documents regarding the Transaction; the risk that the either Sphere or Cathedra may terminate the Agreement and either Sphere or Cathedra is required to pay a termination fee to the other party; the ultimate timing, outcome and results of integrating the operations of Sphere and Cathedra; the ultimate timing, outcome and results of integrating the operations of Sphere and Cathedra; the effects of the business combination of Sphere and Cathedra, including the Combined Company's future financial condition, results of operations, strategy and plans; the ability of the Combined Company to realize anticipated synergies in the timeframe expected or at all; changes in capital markets and the ability of the Combined Company to finance operations in the manner expected; the risk of any litigation relating to the proposed Transaction; the risk of changes in governmental regulations or enforcement practices; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws and regulations both locally and in foreign jurisdictions; compliance with extensive government regulation and the costs associated with compliance; unanticipated costs; the risks and uncertainties associated with foreign markets; the diversion of management time on the Transaction; the volatility of bitcoin prices and other digital asset markets; changes in network difficulty, hash rate or mining economics; the availability, cost and reliability of power and energy infrastructure; the ability to secure additional power capacity or execute expansion projects on time and within budget; delays in delivery, installation or performance of mining equipment or other critical infrastructure; cybersecurity threats, technology failures or data center outages; counterparty risks relating to hosting clients, equipment suppliers or power providers; the availability and retention of key personnel; the ability to access debt or equity financing on acceptable terms; and risks related to competition in the bitcoin mining and high-performance computing industries. Additionally, the forward-looking statements contained herein may be affected by risks and uncertainties in the business of Cathedra and Sphere and general market conditions.

Additional factors that could cause results to differ materially from those described above can be found in Sphere's reports filed on Form 10-K, Form 10-Q and Form 8-K and in other filings made by Sphere with the SEC from time to time and available at www.sec.gov and available on Sphere's website at www.sphere3d.gcs-web.com under the "Financials" tab, and in Cathedra's management information circular dated October 30, 2025 available under the Cathedra's issuer profile on SEDAR+ at www.sedarplus.ca and in other documents Cathedra files on SEDAR+.

All forward-looking statements speak only as of the date they are made and are based on information available at that time. Neither Cathedra nor Sphere assumes any obligation to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by applicable securities laws. As forward-looking statements involve significant risks and uncertainties, caution should be exercised against placing undue reliance on such statements. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Cathedra and Sphere have attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. Readers should not place undue reliance on forward-looking information.

FINANCIAL INFORMATION

This news release contains future-oriented financial information and financial outlook information (collectively, "FOFI") about prospective results of operations, future net revenue, share capital, cash flows, and components thereof, all of which are subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraphs. FOFI contained in this news release was made as of the date of this news release and was provided for the purpose of providing information about management's current expectations and plans relating to the future. Readers are cautioned that the forward-looking statements and FOFI contained in this document should not be used for purposes other than for which it is disclosed herein. The forward-looking statements and FOFI contained in this news release are expressly qualified by this cautionary statement. Certain information contained herein is based on, or derived from, information provided by independent third-party sources. Cathedra and Sphere believe that such information is accurate and that the sources from which it has been obtained are reliable. Cathedra and Sphere cannot guarantee the accuracy of such information, however, and have not independently verified the assumptions on which such information is based. Cathedra and Sphere do not assume any responsibility for the accuracy or completeness of such information. Cathedra and Sphere do not intend, and do not assume any obligation, to update the forward-looking statements or FOFI contained in this news release except as otherwise required by applicable law.

This press release contains certain non-GAAP and non-IFRS financial measures, which management believes may enable investors to better evaluate Cathedra's and Sphere's performance, liquidity and ability to generate cash flow. These measures do not have any standardized definition under U.S. GAAP or IFRS, and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with U.S. GAAP or IFRS, as applicable. Other companies may calculate these measures differently.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286434

Source: Cathedra Bitcoin Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

A Johnson & Johnson banner is displayed on the front of the New York Stock Exchange (NYSE) in New York City, in New York City, U.S., December 5, 2023. REUTERS/Brendan McDermid Purchase Licensing Rights, opens new tab

CompaniesWASHINGTON, March 5 (Reuters) - Two Johnson & Johnson (JNJ.N), opens new tab units have agreed to pay $65 million to settle a proposed antitrust class action by health plans and others claiming they were ​overcharged for the pulmonary hypertension drug Tracleer.

The preliminary settlement, opens new tab with Actelion Pharmaceuticals and ‌Janssen Research & Development was filed on Wednesday in the federal court in Maryland. The proposal requires approval from a judge.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

The plaintiffs, including the Government Employees Health Association and other entities that paid or ​provided reimbursement for their members' use of Tracleer, alleged in their lawsuit that ​the drugmakers delayed competition for a generic version of the medication.

Actelion ⁠made billions of dollars in profits from selling Tracleer, an oral treatment for pulmonary ​artery hypertension. Johnson & Johnson in 2017 completed its acquisition of Actelion. Janssen is also a ​part of Johnson & Johnson.

Johnson & Johnson did not immediately respond to a request for comment.

Sharon Robertson, a lead attorney for the plaintiffs, said the settlement will provide "meaningful relief" for the class of so-called third-party ​payors that purchased Tracleer and its generic version over the span of nearly a ​decade.

The defendants denied any wrongdoing in agreeing to settle the case, which was first filed in 2018.

The ‌lawsuit ⁠alleged the drugmakers impeded competitor access to samples of Tracleer, which they said “effectively blocked competitors from bringing a competing generic product to market for a period of time.”

The settlement covers Tracleer purchases in 31 states, the District of Columbia and Puerto Rico between December ​2015 and September 2024.

The ​plaintiffs said they ⁠plan to seek up to about 33% of the settlement fund for legal fees, or about $21 million.

The case is Government Employees Health ​Association v. Actelion Pharmaceuticals Ltd et al, U.S. District Court ​for the ⁠District of Maryland, No. 1:18-cv-03560-GLR.

For plaintiffs: Sharon Robertson of Cohen Milstein Sellers & Toll; and Thomas Sobol of Hagens Berman Sobol Shapiro

For defendants: William Cavanaugh Jr of Patterson Belknap Webb & Tyler; and ⁠Shari ​Ross Lahlou of Dechert

Read more:

Reporting by Mike Scarcella

Our Standards: The Thomson Reuters Trust Principles., opens new tab

SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it intends to offer and sell, subject to market and other conditions, units consisting of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. Each share of common stock or pre-funded warrant will be sold with accompanying common warrants to purchase shares of common stock (or a pre-funded warrant in lieu thereof). The shares of common stock, pre-funded warrants and/or common warrants comprising the units will be separated immediately upon issuance. The purchase price of each pre-funded warrant will equal the price per share at which shares of common stock are being sold to the public in the offering, minus $0.001, the per share exercise price of each pre-funded warrant. In addition, the Company expects to grant the underwriters a 45-day option to purchase up to an additional 15% of the number of shares of common stock and/or common warrants to purchase shares of its common stock offered in the public offering at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock, pre-funded warrants and common warrants are being offered by the Company.

The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager for the offering.

Calidi intends to use the net proceeds from the offering for working capital and for general corporate purposes.

The securities described are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-284229), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on February 7, 2025. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been or will be filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at [email protected]. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described therein, nor shall there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Calidi 

Calidi Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company’s proprietary Redtail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.

CLD-401, the lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the Redtail platform including its novel approach to incorporate BiTEs in solid tumors.

Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com or view Calidi’s Corporate Presentation here.

Forward-Looking Statements

This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning key milestones, including certain pre-clinical data, planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s annual report filed with the SEC on Form 10-K on March 31, 2025, as may be amended or supplemented by other reports we file with the SEC from time to time. We disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

For Investors:

Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
[email protected]

March 05, 2026 18:00 ET  | Source: Belo Sun Mining Corp.

TORONTO, March 05, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX:BSX, OTCQB:BSXGF) is pleased to announce that Mr. Benjamin Buckingham has been nominated by La Mancha Investments S. à r. l. (“La Mancha”) to serve as its representative on the Board of the Company pursuant to the investor rights agreement between the Company and La Mancha.

Mr. Buckingham replaces Mr. Jack Lunnon, who has stepped down as a director of the Company effective March 5, 2026 in connection with La Mancha’s internal transition of its Board representation.

The Company thanks Mr. Lunnon for his service and contribution during his tenure as a director. Mr. Lunnon will continue in his role as Chief Technical Officer of the La Mancha group and will remain engaged in supporting Belo Sun through La Mancha’s ongoing involvement.

Mr. Buckingham has over 10 years of experience in metals and mining investment and finance. He has been with La Mancha since 2020 and currently serves as Vice President, Investments, where he is responsible for sourcing and evaluating investment opportunities, conducting due diligence and valuations, executing transactions, and providing portfolio oversight and strategic support. Mr. Buckingham has been closely involved in La Mancha’s investment in Belo Sun and has been responsible for executing several investments, primarily in Brazil and Latin America. He has experience supporting portfolio companies through M&A, corporate development and project financing initiatives.

Prior to joining La Mancha, Mr. Buckingham was an Investment Analyst at CD Capital, a mining-focused private equity firm. He holds an MSc in Metals and Energy Finance from Imperial College London and a BA (Hons) in Economics from the University of Newcastle.

Clovis Torres, Chairman and Chief Executive Officer of Belo Sun, commented: “We would like to thank Jack for his valuable contribution to the Board and for his continued support of Belo Sun through La Mancha’s ongoing involvement. We are pleased to welcome Ben Buckingham as La Mancha’s nominee and look forward to working with him as we advance the Volta Grande Project. Ben’s experience in corporate development and project financing will be a valuable addition to the Board as we continue progressing the development of the Project.”

About the Company

Belo Sun Mining Corp. is a mineral exploration and development company with gold-focused properties in Brazil. Belo Sun’s primary focus is advancing and expanding its 100% owned Volta Grande Gold Project in Pará State, Brazil. Belo Sun trades on the TSX under the symbol “BSX” and on the OTCQB under the symbol “BSXGF.” For more information about Belo Sun, please visit www.belosun.com.

For inquiries, please contact Belo Sun Mining Corp, 1-888-516-4171 or [email protected].

Caution regarding forward-looking information:

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the appointment of Mr. Buckingham to the Board of the Company; and the departure of Mr. Lunnon as a director. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including risks inherent in the mining industry and risks described in the public disclosure of the Company which is available under the profile of the Company on SEDAR+ at www.sedarplus.ca and on the Company's website at www.belosun.com. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Vancouver, British Columbia--(Newsfile Corp. - March 5, 2026) - Nexus Uranium Corp. (CSE: NEXU) (OTCQB: NEXUF) (FSE: JA7) ("Nexus" or the "Company") announces that further to its news release dated February 10, 2026, it has issued 42,408 common shares of the Company at a deemed price of $1.91 per share to a certain arm's length creditor, pursuant to a debt settlement agreement with the arm's length creditor to settle $81,000 in outstanding debt (the "Debt Settlement").

The Company completed the Debt Settlement to preserve the Company's cash for working capital and improve its financial position by reducing its existing liabilities.

The Debt Settlement shares are subject to a four month hold period in accordance with applicable Canadian securities laws and the policies of the Canadian Securities Exchange.

About Nexus Uranium Corp.

Nexus Uranium is a Canadian exploration company focused on uranium projects in North America. In the United States, the Company holds the Chord, Wolf Canyon, Deadhorse, and RC projects in South Dakota, and the South Pass project in Wyoming. The Great Divide Basin project in Wyoming is now under option to Canamera Energy Metals Corp. In Canada, Nexus holds the Mann Lake project in Saskatchewan's Athabasca Basin. For more information, visit www.nexusuranium.com.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286386

Source: Nexus Uranium Corp.

, /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing an updated notice to investors in BellRing Brands, Inc. (NYSE: BRBR) regarding the March 23, 2026, lead plaintiff deadline accusing BellRing and certain of BellRing's top executives of securities fraud.

CLICK HERE TO SUBMIT YOUR BRBR LOSSES NOW

The suit alleges Defendants misled investors about the true drivers of BellRing's 2025 sales growth. The truth emerged over a series of disclosures revealing that growth was allegedly fueled by retailers "hoarding inventory" to safeguard against prior supply chain shortages. When retailers finally moved to "destock" these excess levels, BellRing's share price collapsed, leading to a 33% single-day crash.

Visit Hagens Berman's dedicated BRBR Case Page: www.hbsslaw.com/cases/bellring
View our latest investigation summary video: youtu.be/

"We are investigating whether BellRing's purported competitive moat was actually a mirage created by retailers over-ordering to avoid empty shelves, as the suit contends" said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the claims alleged in the pending suit.

BellRing Brands, Inc. (BRBR) Securities Class Action:

The pending litigation alleges that BellRing and its executives issued misleading statements regarding the strength, sustainability, and drivers of its sales growth, as well as the impact of competition on demand for its products.

Concealed Inventory Hoarding: The complaint alleges that BellRing's strong reported sales during the Class Period did not reflect end-consumer demand or brand momentum. Instead, the results were materially attributable to temporary inventory stockpiling by several of its key customers as a safeguard against product shortages that had previously constrained BellRing's supply. Foreseeable Drop Off: The lawsuit claims that once BellRing's customers gained confidence that product shortages were over, they promptly reduced their inventory by selling through their overstocked inventory and reduced new orders. The "Hoarding Inventory" Admission: On May 6, 2025, after BellRing reported disappointing Q2 2025 financial results, BellRing's CFO revealed that during the quarter "several key retailers lowered their weeks of supply on hand[,]"a couple of retailers "were a little bit hoarding inventory to make sure they didn't run out of stock on the shelf[,]" and "[w]e thought this could happen." But the CFO downplayed the headwind by assuring investors that "absolutely, no softness, no concern around consumption." This news sent the price of BellRing shares down $14.88 (-19%). Earnings Collapse and Severe Market Reaction: On Aug. 4, 2025, BellRing reported Q3 2025 financial results revealing a disappointing narrowed sales outlook range. BellRing's CFO blamed increasing competition and "consumption" had not outpaced "shipments." But, one analyst expressed skepticism, pointing out "I might have expected consumption to be much higher given there was some destock in the third quarter." This news sent the price of BellRing shares down $17.46 (-33%). Next Steps: Contact Partner Reed Kathrein Today

Hagens Berman is a top-tier plaintiff litigation firm recognized for leading complex securities fraud class actions.

Mr. Kathrein is actively advising investors who purchased BRBR shares between November 19, 2024 – August 4, 2025 and suffered substantial losses.

The Lead Plaintiff Deadline is March 23, 2026.

TO SUBMIT YOUR BELLRING (BRBR) LOSSES NOW, PLEASE USE THE SECURE FORM BELOW:

Click Here to Report Your BRBR Losses to Hagens Berman If you'd like more information and answers to frequently asked questions about the BellRing case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding BellRing should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

SOURCE Hagens Berman Sobol Shapiro LLP

NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Hub Group, Inc. (NASDAQ: HUBG) resulting from allegations that Hub Group may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Hub Group securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=52777 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On February 5, 2026, after market hours, Hub Group filed a Current Report with the Securities and Exchange Commission on Form 8-K announcing preliminary financial results for the full year and fourth quarter ended December 31, 2025. The report stated that “[i]n connection with the preparation of its financial statements for the year ended December 31, 2025, the Company identified an error that resulted in the understatement of purchased transportation costs and accounts payable in the first nine months of 2025.” As a result of the error, Hub Group “plans to restate its financial statements for the first, second and third quarters of 2025.”

On this news, Hub Group’s stock price fell $9.37 per share, or 18.3%, to close at $41.96 per share on February 6, 2026. 

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

By You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Costco is suing the US government for refunds of Trump's IEEPA tariffs. Kevin Carter/Getty Images 2026-03-05T23:04:11.788Z

Costco CEO Ron Vachris said the company is committed to returning tariff refund value to members. The company is one of hundreds suing the US government for refunds of Trump's IEEPA tariffs. "We always want to be the first to lower prices and the last to raise them," Vachris said. Costco CEO Ron Vachris said the company is committed to returning tariff refund value to members.

"Regarding tariff refunds, it is not yet clear what the process will be, what refunds, if any, will be received, and when this will happen," Vachris said during the wholesale clubs' quarterly earnings call on Thursday.

"When legal challenges have recovered charges passed on in some form to our members, our commitment will be to find the best way to return this value to our members through lower prices and better values," he added.

Costco is one of hundreds of companies suing the US government for refunds of Trump's IEEPA tariffs, which were struck down by the Supreme Court last month.

Vachris said the company has also taken several steps to manage the impact of tariffs on its pricing, including shifting countries of origin for certain items, consolidating global purchases, and leaning into its own Kirkland Signature brand.

Those steps will give the company an advantage as the replacement global tariffs take over from the overturned IEEPA rules, he said. "We believe our expertise in buying and our limited SKU-count model puts us in a position to manage this as well as anyone."

The timing and layering of different tariff rates throughout the year have also made it difficult to track the exact impact on specific items, Vachris said, but the company has lowered prices on items like textiles, bedding, and cookware as some tariffs have decreased.

"At Costco, we always want to be the first to lower prices and the last to raise them," he said.

Costco Tariffs

Read next

KuCoin has unveiled KCS PulseDrop, an ambitious strategic initiative designed to expand the utility of its native token (KCS). The platform reported that they aim to transform user interaction into a “participation economy,” allowing everyday activities such as trading, staking, and using the KuCard to generate tangible rewards in a transparent manner.

This transition allows KCS to move from being a passive holding asset to a dynamic tool that bridges the world of traditional finance with digital assets. By integrating payments through KuCoin Pay and P2P transactions into the points system, they foster long-term loyalty and democratize access to rewards based on actual activity, rather than prioritizing solely the size of the invested capital.

In the coming days, investors should keep a close eye on the implementation of point multipliers and the impact of this infrastructure on the mass adoption of the token within the more than 200 countries where the firm operates. The consolidation of this participatory ecosystem is expected to position KuCoin competitively against other industry giants, while it advances its regulated expansion under international security standards.

Source: https://goo.su/GkcJ

Disclaimer: Crypto Economy’s Flash News is prepared from official and public sources verified by our editorial team. Its purpose is to provide quick information about relevant events in the crypto and blockchain ecosystem. This information does not constitute financial advice or investment recommendations. We recommend always verifying the official channels of each project before making related decisions.

Bitcoin surged above $70,000 this week as markets reacted to escalating conflict between the United States and Iran. However, Peter Schiff renewed his criticism of Bitcoin, arguing the rally could mislead investors during wartime volatility. Earlier, Schiff warned that Bitcoin above $71,000 represented a “head fake,” urging investors to sell Bitcoin and move funds into gold or silver.

Peter Schiff Doubles Down on Gold During War Uncertainty Peter Schiff, on X, issued his latest warning as global markets digested rising geopolitical tensions linked to the U.S.-Iran conflict. He argued that investors currently expect the war to remain short and manageable. However, Schiff said that outcome remains unlikely and explained that markets could shift quickly if the conflict drags on longer than expected.

According to Schiff, a prolonged war would pressure stocks, bonds, cryptocurrencies, and the U.S. dollar. At the same time, he expects oil and gold prices to climb significantly. His comments come during a period when oil prices have surged after the conflict disrupted key energy routes.

However, gold declined despite the geopolitical tensions, while Bitcoin moved in the opposite direction and continued rising. This price divergence added a new outlook to the debate over safe-haven assets, since gold traditionally attracts investors during wartime uncertainty and market stress. Yet recent market moves showed Bitcoin gaining while gold pulled back.

Bitcoin Surges as Analysts Debate Safe-Haven Narrative While Schiff criticized Bitcoin’s rally, other market voices addressed the unusual price behavior. As CoinGape reported, billionaire hedge fund founder Ray Dalio also questioned comparisons between Bitcoin and gold. Dalio argued that Bitcoin lacks central bank backing and offers limited privacy advantages, while also warning that future quantum computing developments could threaten the cryptocurrency’s security model.

These remarks came as Bitcoin outperformed gold during the latest U.S.-Iran conflict. The contrast between the two assets became more visible after Iranian airstrikes intensified regional tensions. However, Bloomberg ETF analyst Eric Balchunas urged caution when interpreting short-term price moves and said recent market behavior does not necessarily redefine Bitcoin or gold as safe-haven assets.

Balchunas noted that Bitcoin gained roughly 12 percent following the Iranian attacks, while gold prices moved lower during the same period. He explained that market-making activity and sentiment shifts likely influenced those movements. 

CryptoQuant Data Shows Relief Rally as Selling Pressure Eases On-chain data shows Bitcoin price’s recent strength. According to CryptoQuant, Bitcoin rallied after selling pressure across spot markets began to decline. Demand contraction narrowed sharply this year, dropping from negative 136,000 BTC early in 2026 to around negative 25,000 BTC recently.

Meanwhile, the Coinbase Premium indicator turned positive, suggesting renewed buying activity from United States investors. The CryptoQuant report also observed reduced selling from traders and long-term holders, while trader unrealized losses reached levels last recorded in July 2022.

Historically, such conditions reduce marginal selling and support short-term rebounds. Long-term holder distribution also slowed significantly in recent months, with the 30-day selling pace falling from 904,000 BTC in November to roughly 276,000 BTC recently. That marked the lowest level recorded since June 2025.

Despite the rebound, CryptoQuant still described current market conditions as bearish overall. Its Bull Score Index remained low at 10 out of 100. The firm also identified two key resistance levels if Bitcoin continues rising, with the first near $79,000 and a stronger resistance appearing around $90,000.

Source: CryptoQuant

Despite XRP (CRYPTO: XRP) declining about 10% over the past month, developments in the broader Ripple ecosystem suggest the XRP Ledger (XRPL) could play an important role in the future of institutional on-chain finance. XRPL Building A Foundation For Institutional Finance Robinson Burkey, co-founder of the Wormhole Foundation, said the XRP Ledger has created a strong foundation by attracting developers and building decentralized finance tools.

Bitcoin (BTC) has just flashed a ‘Death Cross,’ a technical signal that has historically preceded major market bottoms. Market analyst CrypFlow, who identified the chart pattern, notes that the current setup is unfolding almost identically to the 2022 bear market cycle. In his analysis, he outlines a potential price target for a Bitcoin bottom and shares what history suggests could come next if the death cross follows the same trajectory as in previous cycles. 

Bitcoin Death Cross Signals More Downside CrypFlow shared his foreboding analysis on X, confirming a Death Cross on the three-day BTC chart that had previously signaled bear-market bottoms. The formation comes as Bitcoin faces significant selling pressure and market volatility, with investor sentiment down the drain and geopolitical tensions fueling more fear and panic, pushing holders to exit the market. 

CrypFlow has stated that the current Death Cross formed against a backdrop of Bitcoin trading around $66,200 at the time of the analysis, with the figure well below the 50 Simple Moving Average (SMA) at $89,799 and the 200 SMA at $91,226. The massive gap between the price and both moving averages underscores how aggressively the market has deteriorated since Bitcoin’s cycle top above $126,000 in October 2025. 

Source: Chart from CrypFlow on X The analyst draws a direct comparison between the current Death Cross and the 2022 bear market cycle, in which an identical Death Cross pattern preceded Bitcoin’s most devastating price crash to a final bottom. In that cycle, CrypFlow noted that the Death Cross formation came after reaching a peak above $66,000. 

Once Bitcoin reached this ATH level, it began trending downwards, forming a Death Cross, which eventually led to a final capitulation low one month later. Interestingly, the cryptocurrency experienced a Double Bottom after crashing again in 2023, with this final decline serving as the foundation for the next bull run. 

Analyst Shares BTC Bottom Target And Timeline The Death Cross pattern is widely recognized as a bearish warning sign, indicating more pain ahead for Bitcoin. Following the 2022 cycle, when the market bottomed roughly one month after the cross was confirmed, CrypFlow has identified March 29, 2026, as a critical window to watch for Bitcoin’s potential price floor this cycle. He suggests a possible target near $50,000, framing the projected one-month timeframe as a historically informed inflection point rather than a guaranteed outcome.  

CrypFlow has outlined three distinct conditions it intends to monitor as that window approaches. The first is continued price weakness into late March, which could serve as a behavioral confirmation that the current cycle is mirroring past patterns. The second condition the analyst is watching for is evidence of seller exhaustion near the March 29 window. 

His third and perhaps most important condition is the reclaiming of key moving averages following any potential bottom. CrypFlow stressed that this reclaim should be viewed as confirmation of a completed bottom.

BTC trading at $72,448 on the 1D chart | Source: BTCUSDT on Tradingview.com Featured image from Getty Images, chart from Tradingview.com

A ceiling of confluent resistance can spell trouble in Shiba Inu’s much-awaited rebound towards $0.0000100.

Market Sentiment:

Bullish Bearish Neutral

Published: March 5, 2026 │ 8:55 PM GMT

Shiba Inu jumped roughly 5% overnight, briefly outperforming a bruised meme-coin complex after a month that’s still deep in the red. The bounce has been enough to get traders watching charts again, but not enough to change the broader shape of the market: Shiba Inu (SHIB) is still coming off a sharp February draw-down of about 21.5%.

The token has been trading around the mid-$0.000005 range, with some market participants describing the move as more of a reflex rally than a clean trend reversal. The backdrop remains cautious, with risk appetite still fragile across high-beta corners of crypto.

Key Levels Are Tightening Into a Range-Bound TradePrice action is increasingly framed by a well-defined band. Several crypto price chart watchers are focused on support near $0.0000055–$0.0000053, a zone that has been tested repeatedly as buyers attempt to defend recent lows.

Sponsored

On the upside, sellers have shown up consistently between roughly $0.0000060 and $0.0000065. A decisive break above that area is widely viewed as the first step toward a larger relief move, with some traders eyeing $0.0000080 as a potential next target if momentum returns and volume confirms.

Momentum indicators have not offered a strong signal. Readings shared by analysts place RSI in the high-30s to low-40s range, implying weakness without the kind of capitulation that typically precedes cleaner rebounds.

On-chain Flows Point To Hesitation, Not Conviction..Behind the candles, the tone looks mixed-to-soft. Measures tied to volume and distribution have been described as trending lower, suggesting the market is not yet seeing broad-based accumulation. Exchange-flow data has also attracted attention after a modest uptick in transfers toward trading venues—often interpreted as potential sell-side supply.

That doesn’t rule out a reversal, but it raises the bar for bulls: holding support is one thing; absorbing overhead supply after weeks of lower highs is another.

Typically, meme coins tend to amplify whatever the broader market decides next. If liquidity improves and risk returns, SHIB is positioned for sharp, technical rallies. If support breaks, the downside can accelerate quickly in a market still short on patience.

Dig into DailyCoin’s trending crypto scoops today:
Analyst Argues XRP’s Real Edge Isn’t Price — It’s Neutrality
Bitcoin Whipsaws From $62.3K Scare To $73K: $80K Next?

People Also Ask:What is Shiba Inu coin (SHIB)?

Shiba Inu is a cryptocurrency that started as a meme coin in 2020, inspired by the Shiba Inu dog (the same breed as Dogecoin’s mascot).

How many SHIB coins exist in total?

There were originally 1 quadrillion SHIB tokens created. About half were sent to Vitalik Buterin (Ethereum co-founder), who burned most of them and donated the rest to charity.

Is SHIB a good investment right now?

SHIB is very high-risk and high-reward — like most meme coins. It can go up a lot during bull markets (it did 10,000x+ in 2021), but occasionally can also drop sharply.

DailyCoin's Vibe Check: Which way are you leaning towards after reading this article?

Market Sentiment

100% Bullish

This article is for information purposes only and should not be considered trading or investment advice. Nothing herein shall be construed as financial, legal, or tax advice. Trading forex, cryptocurrencies, and CFDs pose a considerable risk of loss.

In brief Dogecoin (DOGE) is down about 8% in the last 24 hours, the biggest fall among top 100 crypto tokens in that time. The token's slide has helped pull down the entire meme category, which is one of the only net losers in the last 24 hours according to CoinGecko. Other popular memes like Pepe, Fartcoin, and Official Trump have also fallen in the last day. A day after leading the crypto market’s top tokens in gains, leading meme coin Dogecoin (DOGE) is atop the pack of losers on Thursday as Bitcoin slides to nearly $71,000 after nearly touching $74,000 on Wednesday for the first time in four weeks.

DOGE has now fallen about 8% in the last 24 hours, turning the token red for the week as it recently changed hands around $0.094. No other coin has fallen harder among the top 100 cryptocurrencies by market cap in the last day, according to CoinGecko.

The fall should not be surprising, according to Bitwise Research Analyst Danny Nelson. 

Nelson told Decrypt on Wednesday that the surge in DOGE alongside the market’s rise was not to be mistaken as the start of a “sustainable meme coin rally.” 

"Dogecoin thrives on the attention economy. It needs to grow its audience to grow in value,” he said, adding that Wednesday’s rally did not provide the appropriate attention catalyst for proper Dogecoin growth. 

After gaining traction in part due to the backing of billionaire Elon Musk, DOGE is now down 87% from its 2021 all-time high of $0.73. 

The token’s daily fall has helped pull down the entire meme coin category, which is the only top 20 market cap category tracked by CoinGecko in the red over the last 24 hours.

The category as a whole has fallen around 0.5% in the last 24 hours and now 8.3% on the week as other notable meme coins like Pepe and Bonk have dipped 5.7% and 2.9% respectively, after a strong Wednesday.

Popular Solana meme coin Fartcoin has fallen around 4.9% in the last 24 hours as well, extending its losses in the last month to 19% as it recently changed hands around $0.16. The token is now down around 93% from its January 2025 all-time high of $2.83.

President Trump’s own official Solana-based meme coin—TRUMP—has suffered a similar fate since that time. The token is down around 6.5% in the last 24 hours, changing hands around $3.23, and now nearly 96% off its all-time high of $73.43.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

As of 4:00 p.m. ET on Thursday, OKB (OKB +18.52%) is among the best-performing cryptocurrencies in the market. This native token of the OKB decentralized exchange (one of the more popular such exchanges) has surged by more than 18% over the past 24 hours, propelling it into the top-40 leaderboard of all digital assets by market capitalization.

Today's Change

(

18.52

%) $

14.48

Current Price

$

92.68

Let's dive into what's moving the needle for OKB right now, given the fact that the overall crypto market is down nearly 3% over the same time frame. Indeed, when one project, such as OKB, is outperforming as it is right now, investors should take note. Let's do just that.

Why is OKB surging today?

Source: Getty Images.

Powering one of the fastest-growing decentralized exchanges in the market, OKB is one top tokens that deserves a look on this basis alone. Over the past day, various reports have highlighted significant surges in trading volume on this platform, with roughly $210 million traded over the past 21 hours (nearly 9% of the token's total market capitalization). That's a big deal for those thinking about which decentralized trading platform users are gravitating toward right now.

Other key drivers of today's move appeared to be strong institutional buying and staking activity, as reflected in OKB's overall total value locked, which has seen a slight uptick in recent days. I'd like to see more on this front (a TVL of just $1.5 million for a project with a market capitalization near $2 billion isn't significant). That said, it's more about trading volumes for this token, and on that front, the growth story for OKB appears to be progressing well.

Chris MacDonald has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

4 mins mins

Tether invests in Axiym to embed USDT in regulated paymentsTether has made a strategic investment in Axiym to embed USDT directly into regulated payment networks, as reported by LiveBitcoinNews. The move targets compliant infrastructure rather than standalone news/crypto/”>crypto rails. The stated objective is to streamline cross-border settlement and broaden merchant and provider access to USDT.

The initiative centers on native integration, so USDT becomes an operational instrument within payment flows. It aligns with models that prioritize AML/KYC controls and Money Services Business (MSB) onboarding. Operational focus points include treasury workflows, settlement timing, and liquidity management.

Why it matters: compliant rails, PNSL efficiency, broader USDT accessEmbedding USDT into regulated rails could lower reconciliation frictions and standardize screening, while maintaining audit trails consistent with onboarding requirements. The Pay-Now, Settle-Later (PNSL) approach separates authorization from final settlement, improving capital efficiency by reducing idle prefunding balances.

according to AInvest’s editorial analysis, PNSL-style flows can unlock liquidity otherwise parked in local accounts for PSPs and remittance providers, while keeping compliance checks upstream. In practice, this may translate into fewer pre-positioned buffers and faster reconciliation cycles for cross-border corridors.

“By supporting native USD₮’s use cases in an advanced payment ecosystem, we are removing barriers to liquidity and simplifying access to the distribution of USD₮, paving the way for more efficient and scalable payments worldwide,” said Paolo Ardoino, CEO of Tether.

BingX: a trusted exchange delivering real advantages for traders at every level.

Near term, the partnership points to cross-border settlement routes that leverage USDT as a unit of account while maintaining regulated on/off-ramps. The expected benefit is lower prefunding and improved cash visibility for providers active in multiple jurisdictions.

For MSBs and payment providers, onboarding remains the gating factor, with AML/KYC procedures and risk scoring required before operational access. Jurisdictional nuances will shape rollout scope, and some markets may demand additional approvals or reporting.

Operationally, integration would align USDT authorization with PNSL-based settlement windows, netting obligations across counterparties and reducing trapped cash. Treasury teams could centralize liquidity and schedule settlements to match risk thresholds and corridor demand.

Compliance, integration, and who benefitsHow AML/KYC and MSB onboarding fit USDT regulated payment networksEmbedding USDT into regulated payment networks implies counterparties complete AML/KYC, sanctions screening, and ongoing monitoring consistent with MSB practices. Providers would map customer due diligence and transaction monitoring to USDT flows, aligning with internal policies and external audits. These controls support traceability, reduce settlement risk, and can ease reconciliation for marketplaces, PSPs, and remittance firms.

Integration model: PNSL mechanics, treasury effects, and cross-border settlementUnder a PNSL model, payers are authorized and funds confirmed at initiation, while final settlement is deferred and often batched across corridors. This lets treasuries net flows, minimize float in local accounts, and concentrate liquidity centrally. Cross-border legs can be settled on schedules aligned to risk appetites and regulatory windows.

At the time of this writing, contextual market background can be drawn from historical USDT price series available on Yahoo Finance.

FAQ about Tether Axiym investmentHow does the Pay-Now, Settle-Later (PNSL) model work and why does it reduce prefunding needs?PNSL authorizes payments instantly and defers final settlement in scheduled batches, enabling providers to net obligations and avoid pre-positioning cash in local accounts.

When will payment providers and merchants be able to use USDT via Axiym and in which countries/currencies?Timelines and coverage were not specified. Availability will depend on MSB onboarding and jurisdictional requirements, with an aim to expand across regulated payment networks.

DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.

Rate this post

Bitcoin's policy outlook brightens as the White House formally nominates Kevin Warsh to lead the Federal Reserve, elevating a former governor who has praised bitcoin as a meaningful financial signal and transformative software innovation. White House Formally Nominates Kevin Warsh as Federal Reserve Chairman The White House on March 4 submitted nominations to the U.S.

Blockchain analytics firm Bubblemaps says it has identified a network of connected wallets that allegedly profited from accurately predicting military strikes involving Iran on the crypto prediction platform Polymarket. The findings have raised questions about whether some traders may have had advance knowledge of geopolitical developments.

In a detailed thread published on X, the analytics firm explained that it traced transactions between several Polymarket accounts that placed highly precise bets on U.S. and Israeli military actions. According to the analysis, a wallet identified as 0xa4eb, operating under the username “nothingeverhappens911,” recently transferred profits off the platform. Tracking those funds led investigators to another Polymarket account known as “Skoobidoobnj,” with the link established through a shared deposit address on Binance.

Further blockchain tracing indicated that the account “Skoobidoobnj” is also connected to two additional Polymarket accounts that appear to have placed similarly timed trades. According to Bubblemaps, one of those accounts earned approximately $65,000 by betting on a U.S. strike on February 28, while another generated about $10,000 by predicting the Israeli operation on June 13. In total, the firm estimates that four linked Polymarket accounts collectively produced about $240,000 in profits by correctly anticipating military developments involving Iran.

The latest analysis follows earlier reports that six recently funded wallets earned roughly $1.2 million by betting that the United States would strike Iran on February 28. Many of those wallets were reportedly funded less than 24 hours before the event and placed bets specifically tied to that date, prompting scrutiny from analysts and policymakers who questioned whether the trades were based on privileged information.

Source: Analysis published by Bubblemaps on X

Disclaimer: This content is for informational purposes only and does not constitute financial advice or an investment recommendation. Digital assets and prediction markets involve significant risk and regulatory uncertainty.

TL;DR:

Solana reached a weekly high of $93.20 before stabilizing in the $89 range. Critical support sits at $85.55, a level that remains intact following the recent rally. Analysts point to $120 as the primary resistance to confirm a structural recovery. Solana’s recent movements have the crypto market on the edge of its seat. After hitting a weekly high of $93.20 on March 5, the asset pulled back and is now trading near $89. This correction follows a week of strength, with Solana climbing from $78 driven by an increase in participation volume.

In the last hour, it fell by 0.77%, but the technical structure remains constructive. In that sense, the $85.55 support level identified by analysts—including Ali Charts—remains untested, meaning the current pullback is a healthy consolidation following the bullish breakout on March 4.

However, for the asset to continue its upward trajectory, it must remain above the current accumulation range. Furthermore, the high transaction volume recently recorded confirms active interest from both buyers and sellers at these price levels.

Structural Levels and the Path Toward Final Recovery In a longer-term view, the outlook for SOL is defined by two critical boundaries: the $120 resistance and the invalidation support at $75. Therefore, a clear breakout above $120 could catalyze an advance toward $140, finally breaking the prolonged downtrend.

On the other hand, if the price falls below $75, the recovery structure would be invalidated. Thus, investors must keep a close watch on the $85 zone, which acts as the immediate safety net before considering more ambitious targets.

Finally, although indicators show accumulation at the base, the Altcoin Season Index suggests that massive market conditions for an explosive rally are not yet present. Meanwhile, Solana continues to build its recovery path, waiting for a catalyst to bridge the gap toward its annual highs.

TLDR: RLUSD’s market cap has more than doubled in six months, per Sentora’s announcement this week. The Sentora vault on Morpho accepts five collateral types: cbBTC, weETH, wstETH, sUSDe, SyrupUSDC. Morpho runs as a permissionless lending network, letting curators set their own risk parameters. The RLUSD vault is live on Ethereum, with Sentora acting as the designated vault curator. Ripple’s RLUSD stablecoin now has a dedicated lending vault on Morpho. Sentora, a DeFi vault curator, launched the product this week. 

The vault allows users to supply RLUSD and earn yield through curated lending markets. It marks another step in pushing RLUSD deeper into on-chain financial infrastructure.

Sentora Builds Curated Lending Market Around RLUSD on Morpho RLUSD has grown steadily since its launch. Its market cap has more than doubled over the past six months, according to Sentora. Much of that growth ties directly to expanding its presence across DeFi protocols and multichain deployments.

The new Morpho vault adds a structured lending venue to that effort. Users deposit RLUSD into the vault. Borrowers can then access that liquidity by posting approved collateral through Morpho’s lending markets.

Sentora controls the risk parameters of the vault. That includes selecting which collateral assets qualify and setting the associated lending terms.

The vault currently accepts five collateral types: cbBTC, weETH, wstETH, sUSDe, and SyrupUSDC. This spread gives borrowers flexibility while maintaining a diversified collateral base for the vault.

Morpho’s Permissionless Design Draws Institutional-Grade Activity Morpho operates as a permissionless, non-custodial lending network. Developers and institutions can build customized lending markets directly on top of its protocol. Rather than relying on shared liquidity pools, the protocol supports curated vaults with configurable risk settings.

That design has driven fast growth. Morpho has become one of the more active lending infrastructures in DeFi, according to Sentora’s announcement.

For RLUSD, the structure offers a clean fit. Sentora manages risk. Morpho handles the underlying infrastructure. Suppliers access yield. Borrowers access stablecoin liquidity.

The vault is now live on Ethereum. Sentora published the contract address and a direct link to the Morpho app interface in its announcement posted on X.

Morpho also flagged the launch on its own X account, describing it as new utility for RLUSD and calling attention to Sentora’s role as curator.

The move signals continued momentum for RLUSD beyond its original issuance role. Stablecoins increasingly function as active settlement assets within DeFi, not just passive stores of value. The Sentora vault adds a concrete use case to that trend.

Bitcoin is consolidating near a crucial support band, with $77,000 emerging as the key level to watch. A breakout above it could signal bullish momentum and a trend reversal, while failure to hold may keep Bitcoin in a corrective phase or push it lower.

Bitcoin Re-Approaches Critical High-Timeframe Support After 0.786 Fibonacci Deviation Crypto analyst Luca highlighted that Bitcoin recently dipped below the high-timeframe support range marked in purple, briefly deviating toward the 0.786 Fibonacci point of interest around $65,900. Following that move, the price is now approaching the previously lost high-timeframe support zone, which coincides with the early April 2025 bottoming structure. This region also overlaps with the 3-day Bull Market Support Band, an area that has served as a strong reversal point several times over the past few months.

Luca explained that this confluence of technical levels is the reason he has not yet reduced his hedge positions. Instead, he prefers to remain cautious until the market provides clearer confirmation of strength. According to Luca, such confirmation would likely come from Bitcoin reclaiming the lost support range or breaking above the Bull Market Support Band.

Source: Chart from Luca on X Until that happens, the analyst warns that the current approach to this zone could still result in a rejection, meaning the move might represent a temporary bounce rather than a confirmed recovery. Luca also emphasized that traders should focus more on protecting capital rather than chasing profits at this stage. Only once clear strength appears, and the probability shifts toward a sustained upside continuation, would it make sense to adopt a more aggressive bullish stance.

$77,000 Emerges As The Critical Confirmation Level For BTC According to Luca, the key confirmation level he is watching right now sits around $77,000. A decisive breakout above that level would signal stronger market momentum. Thus, Luca plans to gradually scale out of his hedge positions and rotate that capital back into his spot holdings, anticipating a more sustainable move to the upside.

Luca also noted that attempting to squeeze out an extra 10–15% gain at current levels may not be the best risk decision. Instead of aggressively chasing short-term profits, he prefers to wait for a clear confirmation that the market structure is shifting in favor of the bulls.

He added that the potential upside could be significantly larger if Bitcoin successfully reclaims the $77,000 level. However, exiting hedge positions too early could expose traders to the risk of a bullish fakeout, where the price briefly moves higher before resuming its downward trend. Because of that possibility, Luca maintains a cautious stance until stronger confirmation appears.

BTC trading at $73,444 on the 1D chart | Source: BTCUSDT on Tradingview.com Featured image from Pixabay, chart from Tradingview.com

March 05, 2026 16:01 ET  | Source: ArriVent BioPharma, Inc.

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 first-line PACC mutant NSCLC study for firmonertinib enrollment underwayADC pipeline advancing with first ADC program, ARR-217, in Phase 1 clinical development Cash and investments of $312.8 million as of December 31, 2025 expected to fund operations into 3Q 2027 NEWTOWN SQUARE, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the year ended December 31, 2025, and highlighted recent Company progress.

“We are advancing firmonertinib toward potential registration, supported by two pivotal programs targeting uncommon EGFR mutations in non-small cell lung cancer (NSCLC), a high unmet need with limited treatment options,” said Bing Yao, CEO of ArriVent. “Our robust clinical data, including CNS activity, underscores the potential of firmonertinib to become a chemotherapy-free standard of care. We look forward to topline pivotal data for firmonertinib monotherapy in frontline EGFR exon 20 insertion mutant NSCLC expected in mid-2026. This is an event driven study, so we plan to continue sharpening our timeline as we look forward to sharing our data.”

Dr. Yao continued, “Our antibody-drug conjugate (ADC) portfolio is also gaining momentum, led by ARR-217, a CDH17-targeted ADC currently in an ongoing Phase 1 trial, with best-in-class potential in gastrointestinal cancers. We expect additional ADC candidates to advance toward the clinic, broadening our pipeline beyond lung cancer into multiple additional solid tumor indications. Backed by a strong balance sheet and a projected cash runway into 3Q 2027, we are well positioned to deliver on our near-term catalysts.”

Recent and Full Year 2025 Highlights

Firmonertinib

Dosed first in patient pivotal ALPACCA study. In December 2025, ArriVent announced dosing of the first patient in the global pivotal Phase 3 ALPACCA study evaluating firmonertinib monotherapy for first-line treatment of epidermal growth factor receptor (EGFR) PACC mutant non-small cell lung cancer (NSCLC) (NCT07185997).Positive final data in EGFR PACC mutant NSCLC. In September 2025, ArriVent presented positive final proof-of-concept data from the randomized global Phase 1b FURTHER trial cohort of first-line firmonertinib monotherapy in patients with NSCLC harboring EGFR PACC mutations at the 2025 World Conference on Lung Cancer (WCLC) (NCT05364073). Firmonertinib demonstrated clinically meaningful progression free survival, central nervous system (CNS) complete responses, and a manageable safety profile consistent with previous trials. We believe this to be the first clinical dataset testing an EGFR inhibitor in a prospectively defined population of EGFR PACC mutant NSCLC.Completed enrollment for pivotal FURVENT trial. During the first quarter of 2025, we completed enrollment in the global pivotal Phase 3 FURVENT study of firmonertinib monotherapy in first-line NSCLC EGFR exon 20 insertion mutations (NCT05607550). Firmonertinib, an oral, highly brain-penetrant, and broadly active mutation-selective EGFR inhibitor, received Food and Drug Administration (FDA) Breakthrough Therapy Designation in this patient population.Received National Medical Products Administration (NMPA) approval in China in second-line EGFR exon 20 insertion mutations.   In February 2026, our partner Shanghai Allist Pharmaceutical Technology Co., Ltd., received NMPA approval for firmonertinib for adults with locally advanced or metastatic NSCLC who have progressed on or after prior platinum-based chemotherapy or who are intolerant to platinum-based chemotherapy and who have been tested for the presence of EGFR exon 20 insertion mutations. Pipeline

Clinical advancement of ADC lead ARR-217 (MRG007). Ongoing Phase 1 dose escalation for ARR-217, a CDH17 targeted ADC, in gastrointestinal malignancies in partnership with Lepu Biopharma Co., Ltd. ArriVent also received FDA IND clearance for ARR-217 and dosed its first patient in March 2026.  Upcoming Milestones

Firmonertinib pivotal EGFR exon 20 insertions data. Top-line firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study for first-line EGFR exon 20 insertions mutant NSCLC is projected to be in mid-2026.IND filing for ARR-002. U.S. IND filing for first-in-class ADC program planned for first half 2026.   Plan to present preclinical data at an upcoming conference.Complete Phase 1 dose escalation for ARR-217. Plan to complete Phase 1 dose escalation and enter into dose optimization for ARR-217, a CDH17 targeting ADC program, in the second half of 2026. 2025 Financial Results

As of December 31, 2025, the Company had cash and investments of $312.8 million, which is expected to fund operations into 3Q 2027. Net cash used in operations was $160.6 million and $70.2 million for the years ended December 31, 2025 and 2024, respectively.Research and development expenses were $153.4 million and $79.0 million for the years ended December 31, 2025 and 2024, respectively. The research and development expenses in 2025 include a one-time upfront payment to Lepu Biopharma Co., Ltd.General and administrative expenses were $24.2 million and $15.3 million for the years ended December 31, 2025 and 2024, respectively.Net loss was $166.3 million and $80.5 million for the years ended December 31, 2025 and 2024, respectively.  About ArriVent
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.

About Firmonertinib

Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. In March 2021, firmonertinib was approved in China for first-line advanced non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletion or L858R mutations and for patients with previously treated locally advanced or metastatic NSCLC with EGFR T790M mutation, otherwise known as EGFR classical mutations.

Firmonertinib was granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for the treatment of patients with previously untreated locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations. Firmonertinib was also granted U.S. FDA Orphan Drug Designation for the treatment of NSCLC with EGFR mutations or human epidermal growth factor receptor 2 (HER2) mutations or HER4 mutations.

Firmonertinib is currently being studied in a global Phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and in a global Phase 3 study in first line NSCLC patients with EGFR PACC mutations (ALPACCA; NCT07185997).

About EGFR mutant NSCLC

Globally, lung cancer is the leading cause of cancer-related deaths among men and women. NSCLC is the predominant subtype of lung cancer, accounting for approximately 85% of all cases. Mutational activation of the EGFR is a frequent and early event in the development of NSCLC. EGFR mutations are divided into classical and uncommon. EGFR exon 20 insertion mutations are a group of uncommon EGFR mutations and constitute approximately 9% of all EGFR mutations. PACC mutations are another group of uncommon EGFR mutations and represent approximately 12% of all EGFR mutations. Patients with NSCLC whose tumors harbor uncommon EGFR mutations have significantly lower life expectancy with available therapies and represent an area of unmet medical need.

About EGFR PACC mutations

P-loop and αC-helix compressing (PACC) EGFR mutations are a distinct set of approximately 70 mostly missense activating mutations within the kinase domain of EGFR. They are similar to exon 20 insertion mutations in narrowing the drug binding pocket to affect tyrosine kinase inhibitor activity. PACC mutations are diagnosed through commercially available NGS and most PCR tests. Patients with PACC mutations have limited treatment options, and there is no broadly utilized standard of care treatment for first-line PACC mutant patients.

About FURVENT

FURVENT is a global, pivotal 3 arm Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with exon 20 insertion mutations being conducted jointly with our partner Allist (NCT05607550). The FURVENT clinical trial is designed to assess the safety and efficacy of firmonertinib administered at either 160 mg or 240 mg, once-daily with each dose being compared to platinum-based chemotherapy with pemetrexed, the current first-line standard of care. The primary endpoint of this study is PFS by BICR per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Secondary endpoints in patients with brain metastases at baseline include brain-specific CNS overall response rate (CNS-ORR) and CNS-PFS by modified RECIST (mRECIST). The study enrolled 398 patients globally, including from sites in the United States, Europe and certain Asian countries including Japan and China.

About ALPACCA

ALPACCA is a global, pivotal 2 arm Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with PACC mutations being conducted jointly with our partner Allist (NCT07185997). The ALPACCA trial is evaluating firmonertinib 240 mg once daily versus investigator’s choice of osimertinib or afatinib in first-line patients with EGFR PACC mutant NSCLC. The 240 mg dose of firmonertinib was selected for pivotal development based on compelling data showing a 16-month median PFS and a confirmed 68% ORR by BICR in the FURTHER trial (NCT05364073). The primary endpoints of this study are ORR and PFS by BICR per RECIST.

Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, cash runway, estimates of our addressable market, activity of firmonertinib compared to available therapies, anticipated clinical milestones, the timing of, and results of, top-line pivotal Phase 3 data for firmonertinib in previously untreated NSCLC patients whose tumors contain EGFR exon 20 insertion mutations, the timing of our planned enrollment of the global pivotal Phase 3 study of firmonertinib in previously untreated NSCLC patients whose tumors contain EGFR PACC mutations, the advancement of the Phase 1 study for ARR-217 in gastrointestinal tumors and the timing of presentation of data from that study, the timing of U.S. IND filing for ARR-002, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2025, to be filed with the Securities and Exchange Commission on March 5, 2026 and our other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law.

 ARRIVENT BIOPHARMA, INC. BALANCE SHEETS(in thousands, except share and per share data)(Unaudited)         December 31,      2025
    2024
Assets          Current assets:        Cash and cash equivalents $45,540  $74,293 Short-term investments  267,281   144,570 Prepaid expenses and other current assets  20,076   8,116 Total current assets  332,897   226,979 Long-term investments  —   47,683 Right of use assets – operating leases  13   154 Deferred offering costs  69   — Other assets  190   126 Total assets $333,169  $274,942        Liabilities and Stockholders’ Equity        Current liabilities:        Accounts payable $5,934  $3,782 Accrued expenses  19,997   13,330 Operating lease liabilities  14   162 Total current liabilities  25,945   17,274 Operating lease liabilities, net of current amount  —   14 Total liabilities  25,945   17,288        Stockholders’ equity:      Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding  —   — Common stock $0.0001 par value, 200,000,000 shares authorized; 42,452,251 and 33,706,765 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively  4   3 Additional paid-in capital  711,847   496,195 Accumulated deficit  (404,641)  (238,333)Accumulated other comprehensive income (loss)  14   (211)Total stockholders’ equity  307,224   257,654 Total liabilities and stockholders’ equity $333,169  $274,942  ARRIVENT BIOPHARMA, INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(in thousands, except share and per share data)(Unaudited)       Year Ended December 31,   2025
    2024
Operating expenses:        Research and development $153,351  $79,004 General and administrative  24,183   15,304 Total operating expenses  177,534   94,308 Operating loss  (177,534)  (94,308)Interest and investment income  11,226   13,820 Net loss  (166,308)  (80,488)Unrealized gain (loss) on marketable securities  225   (211)Total other comprehensive gain (loss)  225   (211)Total comprehensive loss $(166,083) $(80,699)       Share information:        Net loss per share attributable to common stockholders, basic and diluted $(4.32) $(2.56)Weighted-average shares of common stock outstanding, basic and diluted  38,462,600   31,469,328 
Contact:
Joyce Allaire
LifeSci Advisors, LLC
[email protected] 

March 05, 2026 16:01 ET  | Source: FormFactor, Inc.

LIVERMORE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- FormFactor, Inc. (NASDAQ: FORM), a leading provider of essential test and measurement technologies enabling next-generation semiconductor innovation, today announced that it will host its Investor Day at the Nasdaq MarketSite in New York City.

Location: Nasdaq MarketSite at 151 W 43rd Street, 10th Floor
Date & Time: May 11th, 2026 from 10:00 am to 1:00 pm Eastern Time

During the event, members of FormFactor’s executive leadership team will provide an in‑depth review of FormFactor’s strategic priorities, long‑term growth opportunities, operational initiatives, and financial targets.

A live webcast and accompanying presentation materials will be available on the Investor Relations section of FormFactor’s website at www.formfactor.com.

A replay of the webcast will also be accessible following the event.

If you are an institutional investor or a financial analyst interested in attending this event in person, please contact [email protected].

About FormFactor:

FormFactor, Inc. (NASDAQ: FORM), is a leading provider of essential test and measurement technologies along the full IC life cycle - from characterization, modeling, reliability, and design de-bug to qualification and production test. Semiconductor companies rely upon FormFactor's products and services to accelerate profitability by optimizing device performance and advancing yield knowledge. The Company serves customers through its network of facilities in Asia, Europe, and North America. For more information, visit the Company's website at www.formfactor.com.

Investor Contact:
Stan Finkelstein
Investor Relations
(925) 290-4273
[email protected]

Source: FormFactor, Inc.

FORM-F

-   Q4 revenue of $32.2 million-   Q4 gross profit increased 9% year-over-year to $24.1 million-   Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively-   Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million-   Paid off an incremental $2 million in principal from term loan during Q4-   OptimizeRx's Board authorizes a $10 million share repurchase program  WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2025.

Financial Highlights

Revenue in the fourth quarter of 2025 remained consistent at $32.2 million when compared to $32.3 million in the same period of 2024. Full year revenue for 2025 came in at $109.4 million, a 19% increase, when compared to $92.1 million in the same year-ago period.Gross profit in the fourth quarter of 2025 increased 9% year-over-year to $24.1 million from $22.0 million in the same period of 2024. Gross profit for the full year of 2025 was $73.6 million an increase from $59.4 million in the same year-ago period.GAAP net income in the fourth quarter of 2025 totaled $5.0 million, or $0.26 per diluted share, compared to net loss of $(0.1) million, or $0.00 per diluted share, in the same period of 2024. GAAP net income for the full year of 2025 totaled $5.1 million, or $0.27 per diluted share, compared to net loss of $(20.1) million, or $(1.10) per diluted share, in the same year-ago period.Non-GAAP net income in the fourth quarter of 2025 totaled $9.9 million, or $0.51 per diluted share, compared to $5.5 million, or $0.30 per diluted share in the same period of 2024. Non-GAAP net income in the full year of 2025 came in at $19.9 million, or $1.05 per diluted share, compared to $6.2 million, or $0.33 per diluted share, in the same year-ago period. (see *Non-GAAP Measures below).Adjusted EBITDA for the fourth quarter of 2025 increased to $12.0 million compared to $8.8 million in the same period of 2024. Adjusted EBITDA for the full year of 2025 came in at $24.3 million compared to $11.7 million in the same year-ago period. (see *Non-GAAP Measures below).Cash and cash equivalents was $23.4 million as of December 31, 2025 as compared to $13.4 million as of December 31, 2024Net cash provided by operating activities was $18.7 million for the year ended December 31, 2025 as compared to $4.9 million in the same period of 2024. Stephen L. Silvestro, OptimizeRx CEO commented, “We delivered a strong fourth quarter, exceeding both consensus and internal expectations, with revenue of $32.2 million and adjusted EBITDA of $12.0 million. For the full year, revenue reached a record $109.4 million and adjusted EBITDA totaled $24.3 million, reflecting more than 20% margin and nearly $19 million in operating cash flow. Importantly, one year ago, we set a goal to become a Rule of 40 company and we have, in 2025, achieved this benchmark demonstrating the strength of our profitable growth model and the durability of our platform. We continue to be focused on becoming a sustainable Rule of 40 company over the next few years.

“We are beginning to see increased market volatility, driven in part by uncertainty surrounding Most Favored Nation (MFN) pricing. In response, we believe some customers are taking a more measured approach to discretionary spending and contract duration. While this dynamic may create some near-term headwinds, we continue to see solid engagement across our network and remain confident in the underlying demand trends supporting our business.

“Against that backdrop, OptimizeRx continues to play a mission-critical role for life sciences companies by enhancing brand visibility, reducing script abandonment, improving interoperability between disparate point-of-care platforms, and supporting the growing shift toward complex specialty medications. In addition, we believe advancements in AI will enable customers to reallocate marketing dollars from content creation toward reach and execution—areas where we provide differentiated value with significant ROIs, further strengthening our position over time.”

 For the Year Ended
December 31, Key Performance Indicators (KPIs)**2025
 2024
  (in thousands, except percentages) Average revenue per top 20 pharmaceutical manufacturers$2,838  $2,976  Percent of total revenue attributable to top 20 pharmaceutical manufacturers 52%  65% Net revenue retention 116%  121% Revenue per average full-time employee$839  $701            Financial Outlook

The Company is also updating its fiscal year 2026 guidance at this time and is expecting revenue to be between $109 million and $114 million with Adjusted EBITDA to be between $21 million and $25 million.

Share Repurchase Program

OptimizeRx’s board of directors has authorized a share repurchase program for up to $10 million of the Company’s outstanding common stock. Under this new program, share repurchases may be made from time to time depending on market conditions, share price, share availability and other factors at the Company’s discretion. This share repurchase authorization is effective March 12, 2026 and expires on the earlier of March 15, 2027, or when the repurchase of $10 million shares has been reached. The Company’s repurchase of shares will take place in open market transactions or privately negotiated transactions in accordance with applicable securities and other laws, including the Securities Exchange Act of 1934. The Company intends to finance the purchase using its available cash and cash equivalents. The Company’s board of directors may modify, suspend, extend or terminate the share repurchase program at any time.

Conference Call, Webcast, and Webcast Replay Information

Date:Thursday, March 5, 2026Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Toll Free:1-844-825-9789International:1-412-317-5180Conference ID: 10206362Call Me:https://callme.viavid.com/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNg==Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1750927&tp_key=099094fd29Call Me Passcode:6586380Webcast Replay:The archived webcast will be on the investor relations section of the OptimizeRx website  Invitation

In an effort to increase relations with institutional investors, OptimizeRx management has dedicated time to hosting individual meetings with portfolio managers and analysts. If you are interested in scheduling a meeting with OptimizeRx management, please contact: [email protected] or [email protected].

*Non-GAAP Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. The reasons why we believe these measures provide useful information to investors and, for historical periods, a reconciliation of these measures to the most directly comparable GAAP measures are included in the supplemental tables that follow.

Although the Company provides guidance for Adjusted EBITDA, a non-GAAP financial measure, it is not able to provide guidance to the most directly comparable GAAP measure. Reconciliations for forward-looking figures would require unreasonable effort at this time because of the uncertainty and variability of the nature and amount of certain components of various necessary GAAP components, including, for example, those related to compensation, acquisition expenses, other income, amortization or others that may arise during the year, and the Company’s management believes such reconciliations would imply a degree of precision that would be confusing or misleading to investors. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

**Definition of Key Performance Indicators

Top 20 pharmaceutical manufacturers: We have updated the definition of “top 20 pharmaceutical manufacturers” in our key performance indicators to be based upon Fierce Pharma’s most updated list of “The top 20 pharma companies by 2024 revenue”. We previously used “The top 20 pharma companies by 2023 revenue”. As a result of this change, prior periods have been restated for comparative purposes.

Net revenue retention: Net revenue retention is a comparison of revenue generated from all clients in the previous period to total revenue generated from the same clients in the following year (i.e., excludes new client relationships for the most recent year).

Revenue per average full-time employee: We define revenue per average full-time employee (FTE) as total revenue over the last 12 months (LTM) divided by the average number of employees over the LTM, which is calculated by taking our total number of FTEs at the end of the prior year period by our total FTE headcount at the end of the most recent period.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com. 

Important Cautions Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s future performance, expected revenues, expected Adjusted EBITDA, plans to grow shareholder value creation, plans to continue the Company’s growth and transformation, plans to position the Company to become a sustained “Rule of 40” company, increased market volatility, engagement across the Company’s network, improving interoperability between disparate point-of-care platforms, growing shift toward complex specialty medications, advancements in AI, plans to pay down debt at an accelerated rate, momentum extending into 2026, setting the stage for sustained strength in 2026 and beyond, the timing and amount of repurchases of our common stock and other statements relating to future performance, plans, and expectations. These forward-looking statements are based on the Company’s current expectations and involve assumptions regarding the Company’s business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, its subsequent Quarterly Reports on Form 10-Q, and in other filings the Company has made and may make with the Securities and Exchange Commission in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

OptimizeRx Contact
Andy D’Silva, Chief Business Officer
[email protected]

Investor Relations Contact
Steven Halper
LifeSci Advisors, LLC
[email protected]

OPTIMIZERX CORPORATION
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
  December 31,  2025
 2024
 ASSETS        Current assets        Cash and cash equivalents$23,365  $13,380  Accounts receivable, net of allowance for credit losses of $260 and $335 at December 31,
2025 and 2024, respectively 37,752   38,212  Taxes receivable 752   —  Prepaid expenses and other 2,846   2,379  Total current assets 64,715   53,971  Property and equipment, net 106   150  Other assets        Goodwill 70,869   70,869  Patent rights, net 4,586   5,517  Technology assets, net 6,870   8,180  Tradename and customer relationships, net 29,340   31,819  Operating lease right-of-use assets 404   366  Security deposits and other assets 28   296  Total other assets 112,097   117,047  TOTAL ASSETS$176,918  $171,168  LIABILITIES AND STOCKHOLDERS’ EQUITY        Current liabilities        Current portion of long-term debt$4,255  $2,000  Accounts payable 1,636   2,156  Accrued expenses 11,591   8,486  Revenue share payable 3,086   5,053  Taxes payable —   318  Current portion of lease liabilities 193   168  Deferred revenue 503   473  Total current liabilities 21,264   18,654  Non-current liabilities        Long-term debt, net 21,421   30,816  Lease liabilities, net of current portion 234   209  Deferred tax liabilities, net 5,705   4,491  Total liabilities 48,624   54,170  Commitments and contingencies        Stockholders’ equity        Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and
outstanding at December 31, 2025 and 2024, respectively —   —  Common stock, $0.001 par value, 166,666,667 shares authorized, 20,500,986 and
20,194,697 shares issued at December 31, 2025 and 2024, respectively 20   20  Treasury stock, $0.001 par value,1,741,397 shares purchased at December 31, 2025 and
2024 (2)  (2) Additional paid-in-capital 207,512   201,348  Accumulated deficit (79,236)  (84,368) Total stockholders’ equity$128,294  $116,998  TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$176,918  $171,168    OPTIMIZERX CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
  For the Three Months Ended
December 31, For the Year Ended
December 31,  2025
 2024
 2025
 2024
                  Net revenue$32,239  $32,317  $109,429  $92,127  Cost of revenues, exclusive of depreciation and
amortization presented separately below 8,139   10,293   35,834   32,749  Gross profit 24,100   22,024   73,595   59,378                   Operating expenses                Stock-based compensation 1,960   2,937   6,962   11,467  Impairment charges 368   —   368   7,489  Depreciation and amortization 1,078   1,094   4,327   4,329  Other general and administrative expenses 12,125   14,358   50,245   49,799  Total operating expenses 15,531   18,389   61,902   73,084  Income (loss) from operations 8,569   3,635   11,693   (13,706) Other income (expense)                Interest expense (1,241)  (1,563)  (5,294)  (6,160) Other income 59   41   198   152  Interest income 84   96   353   329  Total other expenses, net (1,098)  (1,426)  (4,743)  (5,679) Income (loss) before provision for income taxes 7,471   2,209   6,950   (19,385) Income tax expense (2,451)  (2,286)  (1,818)  (725) Net income (loss)$5,020  $(77) $5,132  $(20,110) Weighted average number of shares outstanding – basic 18,661,212   18,418,519   18,555,343   18,292,935  Weighted average number of shares outstanding – diluted 19,381,024   18,418,519   18,998,463   18,292,935  Income (loss) per share – basic$0.27  $—  $0.28  $(1.10) Income (loss) per share – diluted$0.26  $—  $0.27  $(1.10)   OPTIMIZERX CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
  For the Year Ended
December 31,  2025
 2024
 OPERATING ACTIVITIES:        Net income (loss)$5,132  $(20,110) Adjustments to reconcile net income (loss) to net cash provided by operating activities:        Depreciation and amortization 4,327   4,329  Impairment charges 368   7,489  Bad debt expense —   208  Stock-based compensation 6,962   11,467  Amortization of debt issuance costs 1,110   835  Change in:        Accounts receivable 460   (2,168) Prepaid expenses and other assets (467)  811  Accounts payable (520)  (72) Revenue share payable (1,967)  (453) Accrued expenses and other liabilities 3,374   1,053  Operating lease liabilities 12   —  Taxes receivable and payable (1,070)  —  Deferred tax liabilities 1,214   1,449  Deferred loan fees (250)  (250) Deferred revenue 30   301  NET CASH PROVIDED BY OPERATING ACTIVITIES 18,715   4,889           INVESTING ACTIVITIES:        Purchases of property and equipment (58)  (112) Capitalized software development costs 126   (338) NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES 68   (450)          FINANCING ACTIVITIES:        Repayment of long-term debt (8,000)  (4,000) Cash paid for employee withholding taxes related to the vesting of restricted stock units (1,150)  (911) Proceeds from exercise of stock options, net of cash paid for withholding taxes 352   —  NET CASH USED IN FINANCING ACTIVITIES (8,798)  (4,911) NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 9,985   (472) CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD 13,380   13,852  CASH AND CASH EQUIVALENTS – END OF PERIOD$23,365  $13,380           SUPPLEMENTAL CASH FLOW INFORMATION:        Cash paid for interest$4,184  $6,203  Cash paid for income taxes$1,760  $161    OPTIMIZERX CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(in thousands, except share and per share data, unaudited)  This earnings release includes certain financial measures not derived in accordance with generally accepted accounting principles (GAAP). These non-GAAP financial measures are measures of performance not defined by accounting principles generally accepted in the United States and should be considered in addition to, not in lieu of, GAAP reported measures. Additionally, these non-GAAP measures may not be comparable to similarly titled measures reported by other companies. However, management believes that presenting certain non-GAAP financial measures provides additional information to facilitate comparison of the Company's historical operating results and trends in its underlying operating results and provides transparency on how the Company evaluates its business. Management uses these non-GAAP financial measures in making financial, operating and planning decisions and in evaluating the Company's performance. Management believes that financial information excluding certain items that are not considered to reflect the Company’s ongoing operating results, such as those listed below, improves the comparability of year-to-year results. Consequently, management believes that investors may be able to better understand the Company’s operating results excluding these items. Non-GAAP financial measures may reflect adjustments for items such as asset impairment charges, amortization, stock-based compensation, acquisition expenses, severance tied to executive departures and reduction in force initiatives, shareholder activist related fees, CEO search fees, other income, as well as other items that management believes are not related to the Company’s ongoing performance.

 For the Three Months Ended
December 31, For the Twelve Months Ended
December 31,  2025
 2024
 2025
 2024
 Net income (loss)$5,020  $(77) $5,132  $(20,110) Deferred income taxes     153   1,215   153  Depreciation and amortization 1,078   1,094   4,327   4,329  Stock-based compensation 1,960   2,937   6,962   11,467  Impairment charges 368   —   368   7,489  Severance charges —   1,183   275   1,908  Shareholder activist related fees —   —   451   —  CEO search fees —   —   225   —  Other income (59)  (40)  (198)  (152) Amortization of debt issuance costs 325   288   1,110   835  Acquisition expense —   —   —   243  Non-GAAP net income     5,538   19,867   6,162                   Non-GAAP net income per share                Diluted$0.51  $0.30  $1.05  $0.33  Weighted average shares outstanding:                Diluted 19,381,024   18,464,605   18,998,463   18,583,936     For the Three Months Ended
December 31, For the Twelve Months Ended
December 31,  2025
 2024
 2025
 2024
 Net income (loss)$5,020  $(77) $5,132  $(20,110) Depreciation and amortization 1,078   1,094   4,327   4,329  Stock-based compensation 1,960   2,937   6,962   11,467  Impairment charges 368   —   368   7,489  Severance charges —   1,183   275   1,908  Acquisition expense —   —   —   243  Shareholder activist related fees —   —   451   —  CEO search fees —   —   225   —  Other income (59)  (40)  (198)  (152) Interest expense (income), net 1,157   1,466   4,941   5,831  Income tax expense 2,451   2,286   1,818   725  Adjusted EBITDA 11,975   8,849   24,301   11,730  

WOODBURY, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced its financial results for its fourth quarter and full year 2025. Management will host a conference call today at 4:30 p.m. Eastern Time to discuss its financial and operating results as well as recent developments.

 •Who: Joseph M. Harary, President & CEO •Date/Time: Thursday, March 5, 2026, 4:30 PM ET •Dial-in Information:1-888-334-5785 •Conference Link: https://join.broaddata.com/?id=research-frontiers •Replay: Available on Friday, March 6, 2026 for 90 days at https://smartglass-ir.com/
Key Highlights for 2025:

1.   First North American OEM Serial Production – Cadillac Celestiq
SPD-SmartGlass entered serial production and customer deliveries on General Motors’ Cadillac Celestiq, marking the first North American OEM production program for SPD-SmartGlass technology. The Cadillac Celestiq program represents a significant validation milestone and establishes a platform for potential expansion into additional, higher-volume vehicle models.
2.   Ferrari Program Transition and Royalty Recognition
During 2025, the Ferrari Purosangue SPD-SmartGlass program transitioned from one European licensed supplier to another. Production levels resulted in minimum annual royalty thresholds exceeded during the third and fourth quarters of 2025.
3.   Architectural Retrofit Market Entry
At GlassBuild America 2025, the Company and its partners introduced a new SPD-SmartGlass retrofit system for the architectural market enabling conversion of existing glazing without full window replacement in homes, apartment buildings, and commercial office and government spaces. This development expands the addressable architectural market beyond new construction into retrofit projects and represents the first scalable pathway for installation into the large installed base of existing buildings.
4.   SPD Film Advancements
The Company and its licensees made significant progress on new types of SPD film designed to enhance optical uniformity, aesthetic integration and manufacturing efficiency. These advancements strengthen SPD’s competitive positioning, especially in the premium automotive and architectural applications.
5.   Expanded Automotive Surface-Area Integration
SPD-SmartGlass continued to be incorporated into concept and evaluation vehicles by global OEMs demonstrating broader glazing applications beyond traditional sunroof installations. The Mercedes Vision V concept integrated SPD across approximately 75% of vehicle glazing, highlighting the potential for materially larger surface-area adoption in future vehicle platforms.
6.   Aerospace Production and Certification Strength
SPD electronically dimmable windows continued flying across more than 40 aircraft models spanning commercial, business and specialty aviation segments, including HondaJet, Textron Beechcraft King Air, Daher TBM 960, Epic E1000, Airbus ACJ TwoTwenty and select Boeing 737 configurations. SPD remains the only commercially available light-control smart window technology known to the Company to have received FAA Supplemental Type Certification (STC) for retrofit programs, reinforcing its differentiated regulatory position and long-standing aviation track record and making SPD-Smart Electronically DimmableWindows (EDWs) uniquely suited for the aftermarket.
7.   Increased Industry Visibility and Leadership
The Company expanded its presence at major global automotive, aerospace and architectural forums. At the Automotive Glazing Summit in Detroit, the Company’s CEO served as Chairman and keynote speaker, reinforcing SPD’s growing recognition within OEM engineering and glazing leadership communities.
8.   Financial Results, Liquidity and Capital Resources
For the year ended December 31, 2025, revenue was approximately $1.12 million and net loss was approximately $2.05 million. During the year, revenue recognition was negatively impacted by the restructuring or bankruptcy of two licensees, which affected timing of royalty flows. The Company ended the year debt-free with approximately $0.7 million in cash and approximately $0.9 million in working capital. Subsequent to year-end, the Company bolstered its balance sheet by raising $1.1 million in a private placement to accredited investors, including members of a director’s family and the Company’s licensee responsible for the architectural retrofit application, further strengthening liquidity entering 2026.

Joseph M. Harary, President and CEO of Research Frontiers noted: “2025 marked a meaningful inflection point for SPD-SmartGlass. We achieved our first North American OEM serial production program with Cadillac Celestiq, successfully transitioned and normalized Ferrari royalty recognition, introduced a scalable architectural retrofit solution, and advanced next-generation black SPD film technology.

Since our last conference call, we have also begun work with several new automotive OEMs in Europe, expanded programs with existing OEMs into higher-volume vehicle models, and initiated specialty automotive and other applications beyond traditional sunroof configurations. While commercialization timing remains dependent on our licensees and their customers, we believe the breadth of ongoing evaluations, expanding surface-area integration, and entry into new application categories position SPD-SmartGlass for broader production deployment and long-term royalty growth.

We believe the foundation now in place across automotive, aerospace and architectural markets creates increasing strategic opportunities and operating leverage as programs mature and move toward higher-volume implementation.”

For more details, please see the Company’s Quarterly Report on Form 10-K which was filed today with the SEC, the contents of which are incorporated by reference herein.

About Research Frontiers

Research Frontiers (Nasdaq: REFR) is a publicly traded technology company and the developer of patented SPD-Smart light-control film technology which allows users to instantly, precisely and uniformly control the shading of glass or plastic products, either manually or automatically. Research Frontiers has licensed its smart glass technology to numerous companies that include well known chemical, material science and glass companies. Products using Research Frontiers’ smart glass technology are being used in tens of thousands of cars, aircraft, yachts, trains, homes, offices, museums and other buildings. For more information, please visit our website at www.SmartGlass.com, and on Facebook, Twitter, LinkedIn and YouTube.

Note: From time to time Research Frontiers may issue forward-looking statements which involve risks and uncertainties. This press release contains forward-looking statements. Actual results, especially those reliant on activities by third parties, could differ and are not guaranteed. Any forward-looking statements should be considered accordingly. “SPD-Smart” and “SPD-SmartGlass” are trademarks of Research Frontiers Inc.

CONTACT:
Joseph M. Harary
President and CEO
Research Frontiers Inc.
+1-516-364-1902
[email protected]

RESEARCH FRONTIERS INCORPORATED
Consolidated Balance Sheets
December 31, 2025 and 2024

       Assets December 31, 2025  December 31, 2024        Current assets:        Cash and cash equivalents $664,299  $1,994,186 Royalties receivable, net of reserves of $1,384,850 and $1,253,450 in 2025 and 2024, respectively  408,666   658,213 Prepaid expenses and other current assets  70,969   93,490 Total current assets  1,143,934   2,745,889          Fixed assets, net  3,393   15,052 Operating lease ROU assets  1,048,352   1,222,640 Deposits and other assets  56,066   56,066 Total assets $2,251,745  $4,039,647          Liabilities and Shareholders’ Equity                 Current liabilities:        Current portion of operating lease liability $146,043  $129,875 Accounts payable  132,666   85,825 Accrued expenses  19,168   53,327 Total current liabilities  297,877   269,027          Operating lease liability, net of current portion  1,020,242   1,166,285 Total liabilities  1,318,119   1,435,312          Shareholders’ equity:        Common stock, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 33,648,221 in 2025 and 2024, respectively  3,365   3,365 Additional paid-in capital  128,552,068   128,177,193 Accumulated deficit  (127,621,807)  (125,576,223)Total shareholders’ equity  933,626   2,604,335          Total liabilities and shareholders’ equity $2,251,745  $4,039,647 
See accompanying notes to consolidated financial statements.

RESEARCH FRONTIERS INCORPORATED
Consolidated Statements of Operations
Years ended December 31, 2025 and 2024

  2025  2024        Fee income $1,121,248  $1,335,531          Operating expenses  2,644,684   2,207,397 Research and development  608,732   570,007 Total expenses  3,253,416   2,777,404          Operating loss  (2,132,168)  (1,441,873)         Net investment income  39,227   95,339 Other income  47,357   35,152          Net loss $(2,045,584) $(1,311,382)         Basic and diluted net loss        per common share $(0.06) $(0.04)         Weighted average number of        common shares outstanding  33,648,221   33,520,904 
See accompanying notes to consolidated financial statements.

RESEARCH FRONTIERS INCORPORATED
Consolidated Statements of Shareholders’ Equity
Years ended December 31, 2025 and 2024

                  Common Stock  Additional Paid-in  Accumulated      Shares  Amount  Capital  Deficit  Total Balance, December 31, 2023  33,509,287  $3,351  $127,779,221  $(124,264,841) $3,517,731 Exercise of options  8,500   1   8,669   -   8,670 Share-based compensation  -   -   89,316   -   89,316 Issuance of common stock and warrants  130,434   13   299,987   -   300,000 Net loss  -   -   -   (1,311,382)  (1,311,382)Balance, December 31, 2024  33,648,221   3,365   128,177,193   (125,576,223)  2,604,335                      Share-based compensation  -   -   374,875   -   374,875 Net loss  -   -   -   (2,045,584)  (2,045,584)Balance, December 31, 2025  33,648,221  $3,365  $128,552,068  $(127,621,807) $933,626                      
See accompanying notes to consolidated financial statements.

RESEARCH FRONTIERS INCORPORATED
Consolidated Statements of Cash Flows
Years ended December 31, 2025 and 2024

  2025  2024 Cash flows from operating activities:        Net loss $(2,045,584) $(1,311,382)Adjustments to reconcile net loss to net cash used in operating activities:        Depreciation and amortization  12,386   26,169 Share-based compensation  374,875   89,316 Credit loss expense  154,253   25,001 ROU asset amortization  174,288   237,394 Change in assets and liabilities:        Royalty receivables  95,294   320,190 Prepaid expenses and other assets  22,521   3,294 Accounts payable and accrued expenses  12,681   74,080 Operating lease liability  (129,875)  (252,881)Net cash used in operating activities  (1,329,161)  (788,819)         Cash flows from investing activities:        Purchases of fixed assets  (726)  (1,623)Net cash used in investing activities  (726)  (1,623)         Cash flows from financing activities:        Net proceeds from exercise of options  -   8,670 Proceeds from issuance of common stock and warrants  -   300,000 Net cash provided by financing activities  -   308,670          Net decrease in cash and cash equivalents  (1,329,887)  (481,772)         Cash and cash equivalents, at beginning of year  1,994,186   2,475,958 Cash and cash equivalents, at end of year $664,299  $1,994,186          Supplemental disclosure of noncash items:        Operating lease assets obtained for operating lease liabilities $-  $1,281,319 
See accompanying notes to consolidated financial statements.